Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
In development
Reference number: GID-TA10391
Expected publication date: TBC
Please note that following on from advice received from the company this evaluation has been rescheduled to align with latest regulatory expectations.
Therefore, we now anticipate that the evaluation will begin during late November 2022 when we will write to you about how you can get involved.